The results of our clinical trial testing the cancer vaccine Ad5-GUCY2C-PADRE in colorectal cancer patients were published in the Journal for ImmunoTherapy of Cancer (JITC).
Josh Barton and John Flickinger, MD/PhD students in our laboratory swept their division of the 2019 Sigma Xi Student Research Day!
The wonderful investigators at the University of Wisconsin Carbone Cancer Center, Department of Human Oncology and McArdle Laboratory for Cancer Research hosted me for their Cancer Biology Seminar series. We got to discuss our work translating new cancer immunotherapies to patients and I learned so much about their clinical experience treating patients with head and neck cancers and their translational research to bring new therapies to their patients.
Our TCR repertoire work was featured on the cover of the Journal of Immunology!
I presented our GUCY2C CAR-T cell work at the Expert Forum on Gastrointestinal Malignancies hosted by Dava Oncology in Dallas, Texas. The forum included myself and 23 experts in GI cancer oncology and surgery. The “Think Tank” was an excellent forum to discuss new data and influence our knowledge, clinical practice, and translational research for GI cancers.
We had a wonderful lunch with potential benefactor Concetta “Chet” Greenberg. She is a remarkable woman with so much energy and wisdom to share.
I recently discussed the possibility for CAR-T cell therapy in colorectal cancer with HemOnc today. Colorectal cancer has not been responsive to immunotherapy, but GUCY2C CAR-T cell therapy may change that. See the discussion here.